Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Lithium Americas Corp (LAC) Price & Performance

Charles River Laboratories Intl. IncTrade
Lithium Americas CorpTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Lithium Americas Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $286.73 (market cap $13.46B), while Lithium Americas Corp trades at $3.26 (market cap $1.18B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 11.4× Lithium Americas Corp's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals.

CRLLAC
Market Cap
$13.46B$1.18B
Sector
HealthBasic Materials
52-Week High
$282.00$10.05
52-Week Low
$145.57$2.71
Enterprise Value
$16.30B$1.29B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.

While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.

Lithium Americas Corp

Lithium Americas Corp. (LAC) trades at $3.30, up 1.54% today, with a bullish technical signal from moving averages but negative profitability metrics including an ROE of -11.35% and net loss of $122.09 million in 2025. Recent news highlights a $175 million financing to strengthen the balance sheet as Thacker Pass approaches peak construction, though earnings have been volatile with mixed quarterly beats and misses.

The outlook is balanced: analyst consensus shows 47% buy ratings with no sells, reflecting optimism on lithium demand, but high execution risk remains given negative cash flow from operations and substantial capital needs. Upside depends on successful project development, while downside risks include funding pressures and commodity price volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Lithium Americas Corp

Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.

Read more on LAC